Amgen

QureBio completed a Series C1 financing round raising nearly CNY 100 million (approximately USD 14 million) led by Efung Capital to accelerate clinical trials of its novel antibody therapeutics.

The global protein therapeutics market reached an estimated $400 billion in value, driven by increasing pharmaceutical company investment in advanced protein-based drug development strategies.

• Black women face disproportionate burden of triple-negative breast cancer with higher incidence and mortality rates, yet comprise only 6.5% of clinical trial participants versus 14.4% US population representation. • Recent advances in small cell lung cancer treatment include promising DLL3-targeting therapy tarlatamab-dlle, offering new hope for patients with disease progression after platinum-based chemotherapy. • FDA's approval of fam-trastuzumab deruxtecan-nxki marks significant progress in site-agnostic cancer therapy, demonstrating efficacy across multiple HER2-positive solid tumors.

BridgeBio Pharma's Attruby (acoramidis) receives FDA approval for transthyretin amyloidosis cardiomyopathy (ATTR-CM), reducing cardiovascular death and hospitalization.

Combination immunotherapies demonstrate superior efficacy compared to monotherapy approaches in NSCLC, with dual checkpoint inhibition and chemo-immunotherapy combinations showing improved overall survival and progression-free survival rates.

Merck has initiated the first Phase 3 clinical program for an oral PCSK9 inhibitor, MK-0616, marking a potential breakthrough in cholesterol treatment with a once-daily pill format.